Efficacy of siRNA-loaded nanoparticles in the treatment of K-RAS mutant lung cancer in vitro

References

• Amelio, I., et al., 2014. Serine and glycine metabolism in cancer. Trends in biochemical sciences, 39, (4), 191–198.
   PubMed Web of Science ®Google Scholar
• Amer, M.H., 2014. Gene therapy for cancer: present status and future perspective. Molecular and cellular therapies, 2, 27.
   PubMedGoogle Scholar
• Arica, B., and Lamprecht, A., 2005. In vitro evaluation of betamethasone-loaded nanoparticles. Drug development and industrial pharmacy, 31, (1), 19–24.
   PubMed Web of Science ®Google Scholar
• Askarian, S., et al., 2015. Cellular delivery of shRNA using aptamer-conjugated PLL-alkyl-PEI nanoparticles. Colloids and surfaces. B, biointerfaces, 136, 355–364.
   PubMed Web of Science ®Google Scholar
• Baysal, I., et al., 2017. Donepezil loaded PLGA-b-PEG nanoparticles: their ability to induce destabilization of amyloid fibrils and to cross blood brain barrier in vitro. Journal of neural transmission, 124, (1), 33–45.
   PubMed Web of Science ®Google Scholar
• Budhian, A., Siegel, S.J., and Winey, K.I., 2007. Haloperidol-loaded PLGA nanoparticles: systematic study of particle size and drug content. International journal of pharmaceutics, 336, (2), 367–375.
   PubMed Web of Science ®Google Scholar
• Chen, H.H., et al., 2015. The metabolome profiling and pathway analysis in metabolic healthy and abnormal obesity. International journal of obesity, 39, (8), 1241–1248.
   Web of Science ®Google Scholar
• Chen, J., et al., 2016. Production and clinical development of nanoparticles for gene delivery. Molecular therapy. Methods & clinical development, 3, 16023.
   PubMed Web of Science ®Google Scholar
• Cho, K., et al., 2008. Therapeutic nanoparticles for drug delivery in cancer. Clinical cancer research, 14, (5), 1310–1316.
   PubMed Web of Science ®Google Scholar
• Choi, Y.S., et al., 2014. Nanoparticles for gene delivery: therapeutic and toxic effects. Molecular & cellular toxicology, 10, (1), 1–8.
   Web of Science ®Google Scholar
• Choosakoonkriang, S., et al., 2001. Infrared spectroscopic characterization of the interaction of cationic lipids with plasmid DNA. The journal of biological chemistry, 276, (11), 8037–8043.
   PubMed Web of Science ®Google Scholar
• Clayton, K.N., et al., 2016. Physical characterization of nanoparticle size and surface modification using particle scattering diffusometry. Biomicrofluidics, 10, (5), 054107.
   PubMed Web of Science ®Google Scholar
• Colombo, S., et al., 2015. Mechanistic profiling of the siRNA delivery dynamics of lipid-polymer hybrid nanoparticles. Journal of controlled release, 201, 22–31.
   PubMed Web of Science ®Google Scholar
• Cross, D., and Burmester, J.K., 2006. Gene therapy for cancer treatment: past, present and future. Clinical medicine & research, 4, (3), 218–227.
   PubMedGoogle Scholar
• Cun, D., et al., 2011. High loading efficiency and sustained release of siRNA encapsulated in PLGA nanoparticles: quality by design optimization and characterization. European journal of pharmaceutics and biopharmaceutics, 77, (1), 26–35.
   PubMed Web of Science ®Google Scholar
• Del Re, M., et al., 2018. Implications of KRAS mutations in acquired resistance to treatment in NSCLC. Oncotarget, 9, (5), 6630–6643.
   PubMedGoogle Scholar
• Devi, G.R., 2006. siRNA-based approaches in cancer therapy. Cancer gene therapy, 13, (9), 819–829.
   PubMed Web of Science ®Google Scholar
• Díez, S., Navarro, G., and De, I., 2009. In vivo targeted gene delivery by cationic nanoparticles for treatment of hepatocellular carcinoma. The journal of gene medicine, 11, (1), 38–45.
   PubMed Web of Science ®Google Scholar
• Duan, J., et al., 2009. Cationic polybutyl cyanoacrylate nanoparticles for DNA delivery. Journal of biomedicine & biotechnology, 2009, 149254.
   PubMedGoogle Scholar
• Eylem, C.C., et al., 2020. Untargeted multi-omic analysis of colorectal cancer-specific exosomes reveals joint pathways of colorectal cancer in both clinical samples and cell culture. Cancer letters, 469, 186–194.
   PubMed Web of Science ®Google Scholar
• Ferlay, J., Laversanne, M., Ervik, M., Lam, F., Colombet, M., Mery, L., Piñeros, M., Znaor, A., Soerjomataram, I., Bray, F. 2020. Global cancer observatory: cancer tomorrow. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/tomorrow, [Accessed 18 Feb 2022].
   Google Scholar
• Fujigaki, S., et al., 2018. Identification of serum biomarkers of chemoradiosensitivity in esophageal cancer via the targeted metabolomics approach. Biomarkers in medicine, 12, (8), 827–840.
   PubMed Web of Science ®Google Scholar
• Gebregiworgis, T., et al., 2017. Glucose limitation alters glutamine metabolism in MUC1-overexpressing pancreatic cancer cells. Journal of proteome research, 16, (10), 3536–3546.
   PubMed Web of Science ®Google Scholar
• Gencer, A., et al., 2021. Recent advances in treatment of lung cancer: nanoparticle-based drug and siRNA delivery systems. Current drug delivery, 18, (2), 103–120.
   PubMed Web of Science ®Google Scholar
• Generosi, J., et al., 2007. Characterization of solid supported lipoplexes by FTIR microspectroscopy. Infrared physics & technology, 50, (1), 14–20.
   Web of Science ®Google Scholar
• Gu, L., et al., 2017. A combination RNAi-chemotherapy layer-by-layer nanoparticle for systemic targeting of KRAS/P53 with cisplatin to treat non-small cell lung cancer. Clinical cancer research, 23, (23), 7312–7323.
   PubMed Web of Science ®Google Scholar
• Haley, B., and Frenkel, E., 2008. Nanoparticles for drug delivery in cancer treatment. Urologic oncology, 26, (1), 57–64.
   PubMed Web of Science ®Google Scholar
• Harguindey, A., et al., 2017. Synthesis and assembly of click-nucleic-acid-containing PEG-PLGA nanoparticles for DNA delivery. Advanced materials, 29, (24), 1700743.
   PubMed Web of Science ®Google Scholar
• Heng, H.H., et al., 2010. The evolutionary mechanism of cancer. Journal of cellular biochemistry, 109, (6), 1072–1084.
   PubMed Web of Science ®Google Scholar
• Jensen, D.K., et al., 2012. Design of an inhalable dry powder formulation of DOTAP-modified PLGA nanoparticles loaded with siRNA. Journal of controlled release, 157, (1), 141–148.
   PubMed Web of Science ®Google Scholar
• Kichler, A., et al., 2001. Polyethylenimine-mediated gene delivery: a mechanistic study. The journal of gene medicine, 3, (2), 135–144.
   PubMed Web of Science ®Google Scholar
• Kopp, F., Wagner, E., and Roidl, A., 2014. The proto-oncogene KRAS is targeted by miR-200c. Oncotarget, 5, (1), 185–195.
   PubMedGoogle Scholar
• Kumar, C. S., 2007. Nanomaterials for medical diagnosis and therapy. Weinheim: John Wiley & Sons.
   Google Scholar
• Lakshmikuttyamma, A., et al., 2014. Stable and efficient transfection of siRNA for mutated KRAS silencing using novel hybrid nanoparticles. Molecular pharmaceutics, 11, (12), 4415–4424.
   PubMed Web of Science ®Google Scholar
• Lee, P.Y., et al., 2012. Agarose gel electrophoresis for the separation of DNA fragments. Journal of visualized experiments, 5,(3), 180–183.
   Web of Science ®Google Scholar
• Lemjabbar-Alaoui, H., et al., 2015. Lung cancer: biology and treatment options. Biochimica et biophysica acta, 1856, (2), 189–210.
   PubMed Web of Science ®Google Scholar
• Li, Y., et al., 2016. Co-delivery of siRNA and hypericin into cancer cells by hyaluronic acid modified PLGA-PEI nanoparticles. Drug development and industrial pharmacy, 42, (5), 737–746.
   PubMed Web of Science ®Google Scholar
• Liu, L., et al., 2016. Hyaluronic acid-modified cationic lipid-PLGA hybrid nanoparticles as a nanovaccine induce robust humoral and cellular immune responses. ACS applied materials & interfaces, 8, (19), 11969–11979.
   PubMed Web of Science ®Google Scholar
• Lu, G., et al., 2019. Improving lung cancer treatment: hyaluronic acid‐modified and glutathione‐responsive amphiphilic TPGS‐doxorubicin prodrug‐entrapped nanoparticles. Oncology reports, 42, (1), 361–369.
   PubMed Web of Science ®Google Scholar
• Lu, P.J., et al., 2020. Ribitol enhances matriglycan of α-dystroglycan in breast cancer cells without affecting cell growth. Scientific reports, 10, (1), 4935.
   PubMed Web of Science ®Google Scholar
• Ma, Z., et al., 2015. MiR-181a-5p inhibits cell proliferation and migration by targeting Kras in non-small cell lung cancer A549 cells. Acta biochimica et biophysica sinica, 47, (8), 630–638.
   PubMed Web of Science ®Google Scholar
• Mansoori, B., Sandoghchian Shotorbani, S., and Baradaran, B., 2014. RNA interference and its role in cancer therapy. Advanced pharmaceutical bulletin, 4, (4), 313–321.
   PubMedGoogle Scholar
• Masood, F., 2016. Polymeric nanoparticles for targeted drug delivery system for cancer therapy. Materials science & engineering. C, materials for biological applications, 60, 569–578.
   PubMed Web of Science ®Google Scholar
• Mehta, A., et al., 2019. Targeting KRAS mutant lung cancer cells with siRNA-loaded bovine serum albumin nanoparticles. Pharmaceutical research, 36, (9), 133.
   PubMed Web of Science ®Google Scholar
• Nemutlu, E., et al., 2019. Metabolic infrastructure of pregnant women with trisomy 21 fetuses; metabolomic analysis. Zeitschrift für geburtshilfe und neonatologie, 223, (05), 297–303.
   PubMed Web of Science ®Google Scholar
• Özgüroğlu, M., 2003. Drug resistance in lung cancer. Eurasian journal of pulmonology, 5, 180–183.
   Google Scholar
• Patil, Y., and Panyam, J., 2009. Polymeric nanoparticles for siRNA delivery and gene silencing. International journal of pharmaceutics, 367, (1–2), 195–203.
   PubMed Web of Science ®Google Scholar
• Perez, C., et al., 2001. Poly(lactic acid)-poly(ethylene glycol) nanoparticles as new carriers for the delivery of plasmid DNA. Journal of controlled release, 75, (1–2), 211–224.
   PubMed Web of Science ®Google Scholar
• Pillai, G.J., Greeshma, M.M., and Menon, D., 2015. Impact of poly(lactic-co-glycolic acid) nanoparticle surface charge on protein, cellular and haematological interactions. Colloids and surfaces. B, biointerfaces, 136, 1058–1066.
   PubMed Web of Science ®Google Scholar
• Ragelle, H., et al., 2014. Chitosan nanoparticles for siRNA delivery: optimizing formulation to increase stability and efficiency. Journal of controlled release, 176, 54–63.
   PubMed Web of Science ®Google Scholar
• Ramalingam, S.S., Owonikoko, T.K., and Khuri, F.R., 2011. Lung cancer: new biological insights and recent therapeutic advances. CA: a cancer journal for clinicians, 61, (2), 91–112.
   PubMed Web of Science ®Google Scholar
• Rao, D.D., et al., 2013. RNA interference and personalized cancer therapy. Discovery medicine, 15, (81), 101–110.
   PubMed Web of Science ®Google Scholar
• Shen, Y., and Li, W., 2018. HA/HSA co-modified erlotinib-albumin nanoparticles for lung cancer treatment. Drug design, development and therapy, 12, 2285–2292.
   PubMed Web of Science ®Google Scholar
• Song, M.S., and Rossi, J.J., 2017. Molecular mechanisms of Dicer: endonuclease and enzymatic activity. The biochemical journal, 474, (10), 1603–1618.
   PubMed Web of Science ®Google Scholar
• Sonke, J.-J., and Belderbos, J., 2010. Adaptive radiotherapy for lung cancered. Seminars in radiation oncology, 20, (2), 94–106.
   PubMed Web of Science ®Google Scholar
• Sundar, R., et al., 2014. Immunotherapy in the treatment of non-small cell lung cancer. Lung cancer, 85, (2), 101–109.
   PubMed Web of Science ®Google Scholar
• Toloza, E.M., Morse, M.A., and Lyerly, H.K., 2006. Gene therapy for lung cancer. Journal of cellular biochemistry, 99, (1), 1–22.
   PubMed Web of Science ®Google Scholar
• Westcott, P.M., and To, M.D., 2013. The genetics and biology of KRAS in lung cancer. Chinese journal of cancer, 32, (2), 63–70.
   PubMed Web of Science ®Google Scholar
• Yuan, T.L., et al., 2014. Development of siRNA payloads to target KRAS-mutant cancer. Cancer discovery, 4, (10), 1182–1197.
   PubMed Web of Science ®Google Scholar
• Zhang, W., et al., 2019. Antitumor effect of hyaluronic-acid-modified chitosan nanoparticles loaded with siRNA for targeted therapy for non-small cell lung cancer. International journal of nanomedicine, 14, 5287–5301.
   PubMed Web of Science ®Google Scholar
• Zou, J., et al., 2019. Hyaluronic acid-modified selenium nanoparticles for enhancing the therapeutic efficacy of paclitaxel in lung cancer therapy. Artificial cells, nanomedicine, and biotechnology, 47, (1), 3456–3464.
   PubMed Web of Science ®Google Scholar